Page 159 - Haematologica - Vol. 105 n. 6 - June 2020
P. 159
Early treatment prediction in Rai 0 CLL
patients classified as high-risk with a CRO score of 5 (27.6 m, 95%CI: 14.4-28.8; P=0.01) (Online Supplementary Table S2 and Online Supplementary Figure S7).
Application of the CRO score in Rai I patients
To assess the generalizability of the CRO score in patients beyond Rai 0 disease, we applied our scoring sys- tem to a consecutive series of Italian multicenter patients with Rai I CLL (375 cases) referred to our center for
AB
immunocytogenic analyses between 2006 and 2017. Our prognostic calculator demonstrated excellent predictive performance in this cohort (c-index 0.67) with a median (95%CI) TFS of 37 m (47-57 m) (Online Supplementary Figure S8).
CRO score variables and TP53 and NOTCH1 mutations Data of TP53 and NOTCH1 mutations were available in 304 of 478 cases from the training cohort. Therefore, a
C
D
E
Figure 3. Laboratory-based prognostic calculator (CRO) score in validation cohorts. Kaplan-Meier curves demonstrating % treatment-free survival (TFS) in the validation cohorts. Gemelli (A), Cardiff (B), Mayo (C), Italian prospective observational study (O-CLL) (D), and composite validation (E) cohorts. Blue: low-risk category; green: moderate-risk category; orange: high-risk category. n: number; y: years; c-index: concordance index.
haematologica | 2020; 105(6)
1617
